-transparent.png){kind=logo}
Pyrido[2,3-d]pyrimidin-7-one inhibitors of cyclin-dependent kinases. 2000
M Barvian, and
D H Boschelli, and
J Cossrow, and
E Dobrusin, and
A Fattaey, and
A Fritsch, and
D Fry, and
P Harvey, and
P Keller, and
M Garrett, and
F La, and
W Leopold, and
D McNamara, and
M Quin, and
S Trumpp-Kallmeyer, and
P Toogood, and
Z Wu, and
E Zhang
Departments of Chemistry and Cancer Research, Parke-Davis Pharmaceutical Research, Division of Warner Lambert Company, 2800 Plymouth Road, Ann Arbor, Michigan 48105, USA.
The identification of 8-ethyl-2-phenylamino-8H-pyrido[2, 3-d]pyrimidin-7-one (1) as an inhibitor of Cdk4 led to the initiation of a program to evaluate related pyrido[2, 3-d]pyrimidin-7-ones for inhibition of cyclin-dependent kinases (Cdks). Analysis of more than 60 analogues has identified some clear SAR trends that may be exploited in the design of more potent Cdk inhibitors. The most potent Cdk4 inhibitors reported in this study inhibit Cdk4 with IC(50) = 0.004 microM ([ATP] = 25 microM). X-ray crystallographic analysis of representative compounds bound to the related kinase, Cdk2, reveals that they occupy the ATP binding site. Modest selectivity between Cdks is exhibited by some compounds, and Cdk4-selective inhibitors block pRb(+) cells in the G(1)-phase of the cell division cycle.
Related Publications
M Barvian, and
D H Boschelli, and
J Cossrow, and
E Dobrusin, and
A Fattaey, and
A Fritsch, and
D Fry, and
P Harvey, and
P Keller, and
M Garrett, and
F La, and
W Leopold, and
D McNamara, and
M Quin, and
S Trumpp-Kallmeyer, and
P Toogood, and
Z Wu, and
E Zhang
April 2005,
Journal of medicinal chemistry,
M Barvian, and
D H Boschelli, and
J Cossrow, and
E Dobrusin, and
A Fattaey, and
A Fritsch, and
D Fry, and
P Harvey, and
P Keller, and
M Garrett, and
F La, and
W Leopold, and
D McNamara, and
M Quin, and
S Trumpp-Kallmeyer, and
P Toogood, and
Z Wu, and
E Zhang
June 2008,
Bioorganic & medicinal chemistry,
M Barvian, and
D H Boschelli, and
J Cossrow, and
E Dobrusin, and
A Fattaey, and
A Fritsch, and
D Fry, and
P Harvey, and
P Keller, and
M Garrett, and
F La, and
W Leopold, and
D McNamara, and
M Quin, and
S Trumpp-Kallmeyer, and
P Toogood, and
Z Wu, and
E Zhang
February 2024,
Journal of medicinal chemistry,
M Barvian, and
D H Boschelli, and
J Cossrow, and
E Dobrusin, and
A Fattaey, and
A Fritsch, and
D Fry, and
P Harvey, and
P Keller, and
M Garrett, and
F La, and
W Leopold, and
D McNamara, and
M Quin, and
S Trumpp-Kallmeyer, and
P Toogood, and
Z Wu, and
E Zhang
June 2023,
European journal of medicinal chemistry,
M Barvian, and
D H Boschelli, and
J Cossrow, and
E Dobrusin, and
A Fattaey, and
A Fritsch, and
D Fry, and
P Harvey, and
P Keller, and
M Garrett, and
F La, and
W Leopold, and
D McNamara, and
M Quin, and
S Trumpp-Kallmeyer, and
P Toogood, and
Z Wu, and
E Zhang
February 2023,
ACS medicinal chemistry letters,
M Barvian, and
D H Boschelli, and
J Cossrow, and
E Dobrusin, and
A Fattaey, and
A Fritsch, and
D Fry, and
P Harvey, and
P Keller, and
M Garrett, and
F La, and
W Leopold, and
D McNamara, and
M Quin, and
S Trumpp-Kallmeyer, and
P Toogood, and
Z Wu, and
E Zhang
November 2019,
Molecules (Basel, Switzerland),
M Barvian, and
D H Boschelli, and
J Cossrow, and
E Dobrusin, and
A Fattaey, and
A Fritsch, and
D Fry, and
P Harvey, and
P Keller, and
M Garrett, and
F La, and
W Leopold, and
D McNamara, and
M Quin, and
S Trumpp-Kallmeyer, and
P Toogood, and
Z Wu, and
E Zhang
February 2009,
Acta crystallographica. Section E, Structure reports online,
M Barvian, and
D H Boschelli, and
J Cossrow, and
E Dobrusin, and
A Fattaey, and
A Fritsch, and
D Fry, and
P Harvey, and
P Keller, and
M Garrett, and
F La, and
W Leopold, and
D McNamara, and
M Quin, and
S Trumpp-Kallmeyer, and
P Toogood, and
Z Wu, and
E Zhang
June 2016,
European journal of medicinal chemistry,
M Barvian, and
D H Boschelli, and
J Cossrow, and
E Dobrusin, and
A Fattaey, and
A Fritsch, and
D Fry, and
P Harvey, and
P Keller, and
M Garrett, and
F La, and
W Leopold, and
D McNamara, and
M Quin, and
S Trumpp-Kallmeyer, and
P Toogood, and
Z Wu, and
E Zhang
April 2015,
Bioorganic & medicinal chemistry letters,
M Barvian, and
D H Boschelli, and
J Cossrow, and
E Dobrusin, and
A Fattaey, and
A Fritsch, and
D Fry, and
P Harvey, and
P Keller, and
M Garrett, and
F La, and
W Leopold, and
D McNamara, and
M Quin, and
S Trumpp-Kallmeyer, and
P Toogood, and
Z Wu, and
E Zhang
April 2008,
Bioorganic & medicinal chemistry letters,
